Dicerna Pharma (DRNA) Misses Q4 EPS by 13c, Beats on Revenues

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/16/2026

1. AMAT
2. GLOB
3. SPY
4. RDDT
5. SNDK
6. HTFL
7. ADYEN:NA
8. DVLT
9. ADYYF
10. WDAY

Go back to Dicerna Pharma (DRNA) Misses Q4 EPS by 13c, Beats on Revenues

Dicerna Pharmaceuticals (DRNA) PT Raised to $15 at SunTrust Robinson Humphrey

March 9, 2018 9:45 AM EST

SunTrust Robinson Humphrey raised its price target on Dicerna Pharmaceuticals (NASDAQ: DRNA) to $15.00 (from $13.00) while maintaining a Buy rating.

Analyst Edward Nash commented, "Yesterday, after the close, Dicerna reported FY2017 financials and provided a corporate update. We are incrementally more positive as... More

Chardan Capital Markets Starts Dicerna Pharmaceuticals (DRNA) at Neutral

March 9, 2018 7:47 AM EST

Chardan Capital Markets initiates coverage on Dicerna Pharmaceuticals (NASDAQ: DRNA) with a Neutral rating saying new investors should wait for a more attractive entry point.

Analsyt Keay Nakae commented, "We believe that Dicerna has the potential to become a significant competitor in the... More

Dicerna Pharmaceuticals (DRNA) PT Raised to $17 at Stifel; Continues to Like the Setup

March 9, 2018 5:55 AM EST

Stifel raised its price target on Dicerna Pharmaceuticals (NASDAQ: DRNA) to $17.00 (from $10.00) while maintaining a Buy rating.

Analsyt Stephen Willey commented, "We continue to like the trajectory of the DRNA story as DCR-PHXC now looks poised for the initiation of a... More